To determine the ideal parameters for both CD38- and CD138-targeted nanoparticle formulations, in vivo biodistribution studies of nanoparticles were analyzed using a subcutaneous xenograft mouse model of multiple myeloma. Here, CD38 is linked to plasma cell myeloma.